Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)35.70
  • Today's Change0.65 / 1.85%
  • Shares traded2.89m
  • 1 Year change+34.72%
  • Beta2.6564
Data delayed at least 15 minutes, as of Nov 14 2024 05:55 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,3501,6512,640
Total Receivables, Net1321,68720
Total Inventory19120.45
Prepaid expenses6.046426
Other current assets, total1.120.311.50
Total current assets2,5083,4142,688
Property, plant & equipment, net685724288
Goodwill, net------
Intangibles, net2,5242,3782,471
Long term investments4989830
Note receivable - long term2.402.332.11
Other long term assets5.506.1618
Total assets5,7736,6156,646
LIABILITIES
Accounts payable494454
Accrued expenses74182133
Notes payable/short-term debt000
Current portion long-term debt/capital leases4144428
Other current liabilities, total13619955
Total current liabilities300870270
Total long term debt49890484
Total debt539535512
Deferred income tax------
Minority interest------
Other liabilities, total6.05----
Total liabilities804960754
SHAREHOLDERS EQUITY
Common stock0.220.210.20
Additional paid-in capital------
Retained earnings (accumulated deficit)4,9045,6455,699
Treasury stock - common0.000.00(59)
Unrealized gain (loss)(230)(187)581
Other equity, total294196(329)
Total equity4,9695,6545,892
Total liabilities & shareholders' equity5,7736,6156,646
Total common shares outstanding319312297
Treasury shares - common primary issue4.3501.62
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.